Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1322888 · 1 trial · 1 indication
includes abnormal clincal lab values, ECGs, vital signs
includes AUC, Cmax, tmax, and t1/2
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects) |
| Cohort 2 | EXPERIMENTAL | GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects) |
| Name | Type | Description |
|---|---|---|
| GSK1322888 | DRUG | 1 mg, 5 mg or 25 mg capsule |
| Placebo | DRUG | matching placebo capsules |
Inclusion Criteria: * AST, ALT, alkaline phosphatase and bilirubin \< or =1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Healthy as determined by a responsible and experienced physician * Male or female between 18 (20 for Japanese) an...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE4 | Tradipitant |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Undisclosed |
GSK1322888 is an investigational small molecule being developed for the treatment of gastroparesis, a gastrointestinal condition. It is currently in Phase 1 clinical development. The drug is being studied to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.
GSK1322888 is being developed by GSK plc, a global biopharmaceutical company. GSK plc is publicly traded under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
GSK1322888 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of single oral doses of the drug in healthy volunteers.
GSK1322888 has one completed Phase 1 clinical trial with the identifier NCT01294566. The trial was a first-time-in-human study evaluating the safety, tolerability, and pharmacokinetics of single oral doses of GSK1322888 in healthy Caucasian and Japanese volunteers. The study enrolled 17 participants and was conducted in Australia.
GSK1322888 is the primary name for this investigational drug. No alternative names have been associated with this compound in the available clinical trial information. It is being studied under this identifier in the clinical trial registry.